(PM P1) 5-hydroxymethylation Signatures in Plasma Circulating Cell-Free DNA as Markers for Appendiceal and Colorectal Peritoneal Metastasis
Saturday, February 15, 2020
12:30 PM – 12:35 PM
Background: Genome-wide mapping of 5-hydroxymethylcytosine (5hmC) on nanogram quantities of peripheral plasma circulating cell-free DNA (PcfDNA) is a promising “liquid biopsy” technique. We aimed to examine if patients with peritoneal metastasis (PM) of colorectal (CRC), high grade appendiceal (HGA) or low grade appendiceal (LGA) cancer origin have distinct signatures of 5hmC in PcfDNA compared to each other and to patients matched for tumors without PM.
Methods: We analyzed plasma samples from a prospectively collected tissue bank. To correlate 5hmC signatures with intraoperative findings, only patients who underwent abdominal surgery in proximity to plasma collection were selected. Key steps of PcfDNA processing included extraction from plasma, nano-hmC-Seal chemical labeling and enrichment of 5hmC-modified fragments, next-generation sequencing, and mapping to the reference human genome.
Results: Plasma samples were collected between 11/2016 – 3/2019 from 46 patients with CRC (n=21), HGA (n=17) and LGA (n=8). Of those, 32 (70%) had PM based on intraoperative findings (median peritoneal cancer index score = 15, range 2-39) and 14 did not have PM. An average of 24.1 million paired-end reads were sequenced for each sample. Four samples (8.7%) were excluded from the analysis due to low sequencing coverage or high duplication level. Unique 5hmC enrichment patterns were found to discriminate with p < 0.05 between CRC PM and HGA PM (n=616 differentially hydroxymethylated genes (DHMGs)), CRC/HGA PM and LGA PM (n=1074 DHMGs), and CRC/HGA PM and CRC/HGA patients without PM (n=1576 DHMGs).
Conclusions: 5hmC signatures in PcfDNA might potentially serve as a sensitive marker of occult PM.